Prognostic indices in diffuse large B‐cell lymphoma in the rituximab era: an analysis of the UK National Cancer Research Institute R‐CHOP 14 versus 21 phase 3 trial.

Saved in:

Bibliographic Details
Title:	Prognostic indices in diffuse large B‐cell lymphoma in the rituximab era: an analysis of the UK National Cancer Research Institute R‐CHOP 14 versus 21 phase 3 trial.
Authors:	Gleeson, Mary^1,2 (AUTHOR), Counsell, Nicholas³ (AUTHOR), Cunningham, David¹ (AUTHOR) david.cunningham@rmh.nhs.uk, Lawrie, Anthony³ (AUTHOR), Clifton‐Hadley, Laura³ (AUTHOR), Hawkes, Eliza^4,5 (AUTHOR), McMillan, Andrew⁶ (AUTHOR), Ardeshna, Kirit M.^7,8 (AUTHOR), Burton, Cathy⁹ (AUTHOR), Chadwick, Nick³ (AUTHOR), Gambell, Joanna³ (AUTHOR), Smith, Paul³ (AUTHOR), Mouncey, Paul³ (AUTHOR), Pocock, Christopher¹⁰ (AUTHOR), Radford, John¹¹ (AUTHOR), Davies, John¹² (AUTHOR), Turner, Deborah¹³ (AUTHOR), Kruger, Anton¹⁴ (AUTHOR), Johnson, Peter¹⁵ (AUTHOR), Linch, David⁷ (AUTHOR)
Source:	British Journal of Haematology. Mar2021, Vol. 192 Issue 6, p1015-1019. 5p.
Database:	Academic Search Ultimate

Description
ISSN:	00071048
DOI:	10.1111/bjh.16691